JP2005533023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533023A5 JP2005533023A5 JP2004505044A JP2004505044A JP2005533023A5 JP 2005533023 A5 JP2005533023 A5 JP 2005533023A5 JP 2004505044 A JP2004505044 A JP 2004505044A JP 2004505044 A JP2004505044 A JP 2004505044A JP 2005533023 A5 JP2005533023 A5 JP 2005533023A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diabetic
- group
- iii
- contained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 19
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 18
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 18
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 15
- 229960004699 valsartan Drugs 0.000 claims description 15
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 claims description 15
- 229960000528 amlodipine Drugs 0.000 claims description 14
- 239000002934 diuretic Substances 0.000 claims description 12
- 230000001882 diuretic effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 21
- 239000000480 calcium channel blocker Substances 0.000 claims 17
- 206010012601 diabetes mellitus Diseases 0.000 claims 14
- 206010019280 Heart failures Diseases 0.000 claims 12
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010002383 Angina Pectoris Diseases 0.000 claims 8
- 208000001647 Renal Insufficiency Diseases 0.000 claims 8
- 201000006370 kidney failure Diseases 0.000 claims 8
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 6
- -1 rasidipine Chemical compound 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 4
- 206010003662 Atrial flutter Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 4
- 208000003782 Raynaud disease Diseases 0.000 claims 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 4
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 4
- 206010039710 Scleroderma Diseases 0.000 claims 4
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims 4
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 210000004204 blood vessel Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims 4
- 206010020718 hyperplasia Diseases 0.000 claims 4
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 4
- 201000001474 proteinuria Diseases 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 3
- VWWMGPCUZVOLLK-UHFFFAOYSA-N 2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid Chemical compound C1CC1C1=NC=2C(C)=CC=NC=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VWWMGPCUZVOLLK-UHFFFAOYSA-N 0.000 claims 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 3
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 3
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 3
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 claims 3
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims 3
- 239000005480 Olmesartan Substances 0.000 claims 3
- 239000005478 Saprisartan Substances 0.000 claims 3
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 claims 3
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 3
- 229960002576 amiloride Drugs 0.000 claims 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 3
- 229960004064 bumetanide Drugs 0.000 claims 3
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 3
- 229960000932 candesartan Drugs 0.000 claims 3
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 3
- 229960002155 chlorothiazide Drugs 0.000 claims 3
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 3
- 229960004166 diltiazem Drugs 0.000 claims 3
- 229960004563 eprosartan Drugs 0.000 claims 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 3
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims 3
- 229960000326 flunarizine Drugs 0.000 claims 3
- 229960003883 furosemide Drugs 0.000 claims 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 3
- 229960003313 hydroflumethiazide Drugs 0.000 claims 3
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 claims 3
- 229960002198 irbesartan Drugs 0.000 claims 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 3
- 229960004773 losartan Drugs 0.000 claims 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 3
- 229960005366 nilvadipine Drugs 0.000 claims 3
- 229960005117 olmesartan Drugs 0.000 claims 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 3
- 229950006241 saprisartan Drugs 0.000 claims 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 3
- 229960002256 spironolactone Drugs 0.000 claims 3
- 229960000651 tasosartan Drugs 0.000 claims 3
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 3
- 229960005187 telmisartan Drugs 0.000 claims 3
- 229960001288 triamterene Drugs 0.000 claims 3
- 229960001722 verapamil Drugs 0.000 claims 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims 2
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 2
- 208000016998 Conn syndrome Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 claims 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010039808 Secondary aldosteronism Diseases 0.000 claims 2
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 claims 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 claims 2
- 229960005081 diclofenamide Drugs 0.000 claims 2
- 229960003580 felodipine Drugs 0.000 claims 2
- 229960002602 fendiline Drugs 0.000 claims 2
- 229960000489 feprazone Drugs 0.000 claims 2
- YONOBYIBNBCDSJ-UHFFFAOYSA-N forasartan Chemical compound N1=C(CCCC)N=C(CCCC)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)N=C1 YONOBYIBNBCDSJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004427 isradipine Drugs 0.000 claims 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 2
- 229960001783 nicardipine Drugs 0.000 claims 2
- 229960001597 nifedipine Drugs 0.000 claims 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
- 229960000715 nimodipine Drugs 0.000 claims 2
- 229960000227 nisoldipine Drugs 0.000 claims 2
- 229960005425 nitrendipine Drugs 0.000 claims 2
- 208000013846 primary aldosteronism Diseases 0.000 claims 2
- 229950003137 tiapamil Drugs 0.000 claims 2
- 229960005461 torasemide Drugs 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000013065 commercial product Substances 0.000 claims 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 1
- 229960003199 etacrynic acid Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims 1
- 229960002817 metolazone Drugs 0.000 claims 1
- 229940036132 norvasc Drugs 0.000 claims 1
- 229960001989 prenylamine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 8
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229940074619 diovan Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940043102 valsartan and amlodipine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38154702P | 2002-05-17 | 2002-05-17 | |
| US60/381,547 | 2002-05-17 | ||
| PCT/EP2003/005180 WO2003097045A1 (en) | 2002-05-17 | 2003-05-16 | Combination of organic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010152053A Division JP2010209123A (ja) | 2002-05-17 | 2010-07-02 | 有機化合物の組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533023A JP2005533023A (ja) | 2005-11-04 |
| JP2005533023A5 true JP2005533023A5 (enExample) | 2006-06-29 |
| JP5132872B2 JP5132872B2 (ja) | 2013-01-30 |
Family
ID=29550142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505044A Expired - Lifetime JP5132872B2 (ja) | 2002-05-17 | 2003-05-16 | 有機化合物の組合せ |
| JP2010152053A Pending JP2010209123A (ja) | 2002-05-17 | 2010-07-02 | 有機化合物の組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010152053A Pending JP2010209123A (ja) | 2002-05-17 | 2010-07-02 | 有機化合物の組合せ |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20050222137A1 (enExample) |
| EP (1) | EP1507529B8 (enExample) |
| JP (2) | JP5132872B2 (enExample) |
| KR (2) | KR20050000546A (enExample) |
| CN (2) | CN101890166A (enExample) |
| AR (1) | AR040014A1 (enExample) |
| AT (1) | ATE429223T1 (enExample) |
| AU (1) | AU2003240261B2 (enExample) |
| BR (1) | BR0310092A (enExample) |
| CA (1) | CA2486144C (enExample) |
| CY (1) | CY1109240T1 (enExample) |
| DE (1) | DE60327316D1 (enExample) |
| DK (1) | DK1507529T3 (enExample) |
| EC (1) | ECSP045429A (enExample) |
| EG (1) | EG24716A (enExample) |
| ES (1) | ES2325207T3 (enExample) |
| IL (1) | IL164925A (enExample) |
| MX (1) | MXPA04011385A (enExample) |
| MY (1) | MY138838A (enExample) |
| NO (1) | NO333011B1 (enExample) |
| NZ (1) | NZ536557A (enExample) |
| PE (1) | PE20040439A1 (enExample) |
| PL (1) | PL372369A1 (enExample) |
| PT (1) | PT1507529E (enExample) |
| RU (1) | RU2324482C2 (enExample) |
| SI (1) | SI1507529T1 (enExample) |
| TW (1) | TWI358291B (enExample) |
| WO (1) | WO2003097045A1 (enExample) |
| ZA (1) | ZA200408737B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2004067003A1 (ja) * | 2003-01-31 | 2004-08-12 | Sankyo Company, Limited | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| WO2004110354A2 (en) | 2003-05-15 | 2004-12-23 | Roskamp Research, Llc | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| US20070054947A1 (en) * | 2003-05-16 | 2007-03-08 | Cohn Jay N | Pharmaceutical composition comprising valsartan |
| JP2009513543A (ja) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロルタリドンの組み合わせ |
| GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
| WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| DE602005018387D1 (de) * | 2004-10-06 | 2010-01-28 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung, verfahren zu ihrer hdihydropyridin-verbindung in einer medizinischen zusammensetzung |
| EA013053B1 (ru) * | 2004-11-05 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Двуслойная таблетка, содержащая телмисартан и амлодипин |
| CN1830454A (zh) * | 2005-03-10 | 2006-09-13 | 刘智仁 | 盐酸在制备治疗高血压药物中的应用 |
| ES2379580T3 (es) * | 2005-04-21 | 2012-04-27 | Santen Pharmaceutical Co., Ltd. | Agente terapéutico para trastorno queratoconjuntival |
| JP5110697B2 (ja) * | 2005-06-27 | 2012-12-26 | 第一三共株式会社 | 固形製剤 |
| TWI405580B (zh) * | 2005-06-27 | 2013-08-21 | Sankyo Co | 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物 |
| JP5063370B2 (ja) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | 湿式造粒製薬の調製方法 |
| DE102005031577A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| CN101460197A (zh) * | 2006-04-06 | 2009-06-17 | 诺瓦提斯公司 | 有机化合物的组合 |
| PE20120542A1 (es) | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| GB2471970A (en) * | 2006-09-15 | 2011-01-19 | Daiichi Sankyo Co Ltd | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide |
| CN101199848B (zh) * | 2006-11-11 | 2012-05-23 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途 |
| CN101801375B (zh) | 2007-01-25 | 2014-01-01 | 韦尔瓦制药有限公司 | 胰岛素增敏剂和治疗方法 |
| GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
| RU2490014C2 (ru) | 2007-10-05 | 2013-08-20 | Альцгеймер'С Инститьют Оф Америка, Инк. | Способ уменьшения отложения амилоида, амилоидной нейротоксичности и микроглиоза с помощью (-)-энантиомера нилвадипина |
| WO2009084003A1 (en) * | 2007-12-31 | 2009-07-09 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
| CN101564536B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物缓控释制剂 |
| WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CN102292085B (zh) | 2009-01-23 | 2017-01-18 | 韩美科学株式会社 | 包含氨氯地平和氯沙坦的固体药物组合物及其制备方法 |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| EP2536396B1 (en) | 2010-02-16 | 2016-08-10 | KRKA, D.D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| RU2425671C1 (ru) * | 2010-06-30 | 2011-08-10 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции нарушений функции почек у больных стабильной стенокардией в сочетании с гипертонической болезнью |
| TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
| GB201116993D0 (en) | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
| KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
| IN2014DN09045A (enExample) | 2012-05-07 | 2015-05-22 | Bayer Pharma AG | |
| WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| MX358211B (es) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
| US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
| EP3025711B1 (en) | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| CN104324377B (zh) * | 2014-06-19 | 2017-08-04 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| KR101914930B1 (ko) * | 2015-03-31 | 2018-11-05 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제 |
| CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| CA3015964C (en) * | 2016-03-24 | 2021-08-03 | Daiichi Sankyo Company, Limited | Medicine for treating renal disease |
| US10319209B2 (en) | 2016-06-03 | 2019-06-11 | John Carlton-Foss | Method and system for motion analysis and fall prevention |
| KR20180053044A (ko) * | 2016-11-11 | 2018-05-21 | 주식회사유한양행 | 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법 |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| AU2018213147B2 (en) * | 2017-01-25 | 2023-08-31 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| LT3658140T (lt) | 2017-02-27 | 2025-08-25 | Idorsia Pharmaceuticals Ltd | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui |
| PL3716979T3 (pl) | 2017-11-30 | 2025-08-04 | Idorsia Pharmaceuticals Ltd | Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endoteliną |
| BR112021001374A2 (pt) * | 2018-07-26 | 2021-07-06 | The George Inst For Global Health | composições para o tratamento da hipertensão |
| CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
| KR20240014345A (ko) | 2022-07-25 | 2024-02-01 | 안국약품 주식회사 | 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US5350771A (en) * | 1989-03-22 | 1994-09-27 | Peter K. T. Pang | Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers |
| CA2016710A1 (en) | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
| US5449682A (en) * | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
| DE59107440D1 (de) * | 1990-02-19 | 1996-04-04 | Ciba Geigy Ag | Acylverbindungen |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| WO1992010097A1 (en) | 1990-12-14 | 1992-06-25 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| US5206348A (en) * | 1992-07-23 | 1993-04-27 | Morton International, Inc. | Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2181461A1 (en) * | 1994-02-08 | 1995-08-17 | Alica Huxley | Treatment of normotensive glaucoma with angiotensin ii antagonists |
| SK117996A3 (en) | 1994-03-17 | 1997-03-05 | Ciba Geigy Ag | Pharmaceutical composition for treatment of diabetic nephropathy |
| GB9406573D0 (en) * | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
| JP4316013B2 (ja) | 1996-03-29 | 2009-08-19 | スミスクライン・ビーチャム・コーポレイション | エプロサルタン二水和物ならびにその製法および処方 |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US5949290A (en) * | 1997-01-14 | 1999-09-07 | Bertram; Earnest L. | Voltage controlled oscillator tuning apparatus and method |
| BR9808521A (pt) | 1997-04-11 | 2000-05-23 | Advanced Medicine Inc | Moléculas que apresentam um grande número de partes ativas. |
| US5991348A (en) * | 1997-08-12 | 1999-11-23 | 3Com Corporation | Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion |
| DE19820151A1 (de) | 1998-05-06 | 1999-11-11 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Candesartan |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| SK285863B6 (sk) * | 1998-07-10 | 2007-10-04 | Novartis Ag | Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín |
| CZ297795B6 (cs) | 1998-12-23 | 2007-03-28 | Novartis Ag | Tablety obsahující valsartan |
| KR100674053B1 (ko) | 1999-01-26 | 2007-01-25 | 노파르티스 아게 | 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도 |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CN1301545A (zh) | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
| DE10004651A1 (de) * | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen |
| PE20020613A1 (es) | 2000-07-19 | 2002-08-07 | Novartis Ag | Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1 |
| EP1353727A2 (en) | 2000-12-01 | 2003-10-22 | Novartis AG | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas |
-
2003
- 2003-05-14 EG EG2003050449A patent/EG24716A/xx active
- 2003-05-15 AR ARP030101691A patent/AR040014A1/es unknown
- 2003-05-15 PE PE2003000470A patent/PE20040439A1/es not_active Application Discontinuation
- 2003-05-15 TW TW092113236A patent/TWI358291B/zh not_active IP Right Cessation
- 2003-05-16 NZ NZ536557A patent/NZ536557A/en not_active IP Right Cessation
- 2003-05-16 WO PCT/EP2003/005180 patent/WO2003097045A1/en not_active Ceased
- 2003-05-16 AT AT03732397T patent/ATE429223T1/de active
- 2003-05-16 PT PT03732397T patent/PT1507529E/pt unknown
- 2003-05-16 CN CN2009102075232A patent/CN101890166A/zh active Pending
- 2003-05-16 JP JP2004505044A patent/JP5132872B2/ja not_active Expired - Lifetime
- 2003-05-16 CA CA2486144A patent/CA2486144C/en not_active Expired - Lifetime
- 2003-05-16 DK DK03732397T patent/DK1507529T3/da active
- 2003-05-16 KR KR10-2004-7018461A patent/KR20050000546A/ko not_active Ceased
- 2003-05-16 MY MYPI20031827A patent/MY138838A/en unknown
- 2003-05-16 BR BR0310092-8A patent/BR0310092A/pt not_active Application Discontinuation
- 2003-05-16 PL PL03372369A patent/PL372369A1/xx not_active Application Discontinuation
- 2003-05-16 RU RU2004137105/15A patent/RU2324482C2/ru not_active IP Right Cessation
- 2003-05-16 KR KR1020117021915A patent/KR101454070B1/ko not_active Expired - Lifetime
- 2003-05-16 EP EP03732397A patent/EP1507529B8/en not_active Revoked
- 2003-05-16 ES ES03732397T patent/ES2325207T3/es not_active Expired - Lifetime
- 2003-05-16 CN CNA038112442A patent/CN1652777A/zh active Pending
- 2003-05-16 AU AU2003240261A patent/AU2003240261B2/en not_active Expired
- 2003-05-16 DE DE60327316T patent/DE60327316D1/de not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011385A patent/MXPA04011385A/es active IP Right Grant
- 2003-05-16 SI SI200331623T patent/SI1507529T1/sl unknown
- 2003-05-16 US US10/514,682 patent/US20050222137A1/en not_active Abandoned
-
2004
- 2004-10-28 IL IL164925A patent/IL164925A/en unknown
- 2004-10-28 ZA ZA200408737A patent/ZA200408737B/en unknown
- 2004-11-12 EC EC2004005429A patent/ECSP045429A/es unknown
- 2004-12-13 NO NO20045429A patent/NO333011B1/no not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/338,066 patent/US8101599B2/en not_active Expired - Fee Related
-
2009
- 2009-07-14 CY CY20091100746T patent/CY1109240T1/el unknown
-
2010
- 2010-07-02 JP JP2010152053A patent/JP2010209123A/ja active Pending
-
2012
- 2012-01-12 US US13/348,833 patent/US20120115854A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533023A5 (enExample) | ||
| JP5132872B2 (ja) | 有機化合物の組合せ | |
| EP1096932B1 (en) | Antihypertensive combination of valsartan and calcium channel blocker | |
| RU2310443C2 (ru) | Синергетические композиции, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| US6395728B2 (en) | Method of treatment and pharmaceutical composition | |
| US6204281B1 (en) | Method of treatment and pharmaceutical composition | |
| JP2016053057A (ja) | 糖尿病の合併症のための療法 | |
| WO2017054787A1 (en) | Pharmaceutical composition comprising the combination of candesartan, amlodipine and hydrochlorothiazide | |
| JP2018111736A (ja) | 高血圧症の予防又は治療のための併用医薬 | |
| JP2005509631A (ja) | Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩 | |
| TW201737909A (zh) | 用以腎臟病之治療的醫藥 | |
| WO2006002983A1 (en) | Combination of organic compounds | |
| HK1036758B (en) | Antihypertensive combination of valsartan and calcium channel blocker | |
| HK1148477A (en) | Combination of organic compounds | |
| CA2677822A1 (en) | Antihypertensive drug combination |